PURPOSE: The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease. Both agents have significant single-agent response rates in this setting. METHODS: GV was given on days 1 and 8 of each 21-day treatment cycle: vinorelbine 25 mg/m(2)/dose administered via intravenous (IV) push before gemcitabine 1,000 mg/m(2)/dose IV over 100 minutes. Any patients who demonstrated a measurable response (complete response [CR], very good partial response [VGPR], or partial response [PR]) were considered to have experienced a response to GV. Response was evaluated after every two cycles. A two-stage minimax rule was used to test the null hypothesis that the response rate is <or= 40% against an alternative hypothesis of a response rate more than 65%. RESULTS: Thirty eligible patients with a median age of 17.7 years (range, 10.7 to 29.4 years) were enrolled. All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone prior autologous stem-cell transplantation. Hematologic toxicity was predominant in all treatment cycles. Nonhematologic grade 3 to 4 toxicity, including elevated hepatic enzymes and hyperbilirubinemia, was less common. Pericardial and pleural effusions developed in one patient after cycles 4 and 5 of GV, consistent with gemcitabine-induced radiation recall. There were no toxic deaths. Measurable responses were seen in 19 (76%) of 25 assessable patients (95% exact binomial CI, 55% to 91%), including six CRs, 11 VGPRs, and two PRs. CONCLUSION: GV is an effective and well-tolerated reinduction regimen for children with relapsed or refractory Hodgkin's disease.
PURPOSE: The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease. Both agents have significant single-agent response rates in this setting. METHODS:GV was given on days 1 and 8 of each 21-day treatment cycle: vinorelbine 25 mg/m(2)/dose administered via intravenous (IV) push before gemcitabine 1,000 mg/m(2)/dose IV over 100 minutes. Any patients who demonstrated a measurable response (complete response [CR], very good partial response [VGPR], or partial response [PR]) were considered to have experienced a response to GV. Response was evaluated after every two cycles. A two-stage minimax rule was used to test the null hypothesis that the response rate is <or= 40% against an alternative hypothesis of a response rate more than 65%. RESULTS: Thirty eligible patients with a median age of 17.7 years (range, 10.7 to 29.4 years) were enrolled. All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone prior autologous stem-cell transplantation. Hematologic toxicity was predominant in all treatment cycles. Nonhematologic grade 3 to 4 toxicity, including elevated hepatic enzymes and hyperbilirubinemia, was less common. Pericardial and pleural effusions developed in one patient after cycles 4 and 5 of GV, consistent with gemcitabine-induced radiation recall. There were no toxic deaths. Measurable responses were seen in 19 (76%) of 25 assessable patients (95% exact binomial CI, 55% to 91%), including six CRs, 11 VGPRs, and two PRs. CONCLUSION:GV is an effective and well-tolerated reinduction regimen for children with relapsed or refractory Hodgkin's disease.
Authors: P L Zinzani; M Bendandi; V Stefoni; P Albertini; F Gherlinzoni; M Tani; P P Piccaluga; S Tura Journal: Haematologica Date: 2000-09 Impact factor: 9.941
Authors: C Nicolaides; M A Dimopoulos; E Samantas; D Bafaloukos; C Kalofonos; G Fountzilas; E Razi; P Kosmidis; N Pavlidis Journal: Ann Oncol Date: 2000-07 Impact factor: 32.976
Authors: E Bajetta; S Chiara Stani; D De Candis; P Bidoli; L Mariani; N Zilembo; P Pozzi; G Procopio Journal: Cancer Date: 2000-08-15 Impact factor: 6.860
Authors: G Frasci; V Lorusso; N Panza; P Comella; G Nicolella; A Bianco; G De Cataldis; A Iannelli; D Bilancia; M Belli; B Massidda; F Piantedosi; G Comella; M De Lena Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: K Akrivakis; P Schmid; B Flath; M Schweigert; O Sezer; H G Mergenthaler; K Possinger Journal: Anticancer Drugs Date: 1999-07 Impact factor: 2.248
Authors: C Gridelli; L Frontini; F Perrone; C Gallo; M Gulisano; S Cigolari; F Castiglione; S F Robbiati; G Gasparini; G P Ianniello; A Farris; M C Locatelli; R Felletti; E Piazza Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: Peter D Cole; Kathleen M McCarten; Richard A Drachtman; Pedro de Alarcon; Lu Chen; Tanya M Trippett; Cindy L Schwartz Journal: Pediatr Hematol Oncol Date: 2010-11 Impact factor: 1.969
Authors: Sagar C Patel; Arnold C Paulino; Danielle Johnston; Lee Wiederhold; Richard Castillo; Rajkumar Venkatramani Journal: Pract Radiat Oncol Date: 2016-06-15
Authors: Justine M Kahn; Kara M Kelly; Qinglin Pei; Rizvan Bush; Debra L Friedman; Frank G Keller; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Sharon M Castellino Journal: J Clin Oncol Date: 2019-09-20 Impact factor: 44.544
Authors: Ajay K Gopal; Oliver W Press; Andrei R Shustov; Stephen H Petersdorf; Ted A Gooley; Jasmine T Daniels; Mitchell A Garrison; George F Gjerset; Matthew Lonergan; Anne E Murphy; Julie C Smith; John M Pagel Journal: Leuk Lymphoma Date: 2010-08
Authors: Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly Journal: Lancet Oncol Date: 2018-08-16 Impact factor: 41.316
Authors: Christopher L Tinkle; Noelle L Williams; Huiyun Wu; Jianrong Wu; Sue C Kaste; Barry L Shulkin; Aimee C Talleur; Jamie E Flerlage; Melissa M Hudson; Monika L Metzger; Matthew J Krasin Journal: Radiother Oncol Date: 2019-02-05 Impact factor: 6.280